================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
July 31, 2003
------------------------------------------------
Date of report (Date of earliest event reported)
CIMA LABS INC.
------------------------------------------------------
(Exact Name of Registrant as Specified in its Charter)
Delaware 0-24424 41-1569769
- ------------------------ ------------------------ -------------------
(State of Incorporation) (Commission File Number) (I.R.S. Employer
Identification No.)
10000 Valley View Road
Eden Prairie, Minnesota 55344-9361
---------------------------------------- ------------
(Address of Principal Executive Offices) (Zip Code)
(952) 947-8700
-------------------------------
(Registrant's Telephone Number,
Including Area Code)
================================================================================
ITEM 12. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
On July 31, 2003, CIMA LABS INC. (the "Company") announced in a
web-cast conference call the following information regarding the Company's
results of operations and financial condition for the quarter ended June 30,
2003:
o Gross margin on net products sales to partners was 39% in the second
quarter.
o Selling, general and administrative expense included approximately $700,000
in expenses related to the patent litigation with KV Pharmaceutical Company
and ETHEX Corporation.
o The Company's capital expenditures totaled approximately $4 million in the
second quarter.
o The Company derived revenue in the second quarter from its significant
partners in approximately the following percentages: Organon -- 53%;
Wyeth -- 20%; AstraZeneca -- 14%; Schwarz Pharma -- 7%.
o The Company derived approximately 54% of its total revenue from sales
targeted for the United States and 46% from sales targeted outside the
United States during the second quarter.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: August 7, 2003
CIMA LABS INC.
By /s/ James C. Hawley
--------------------------------
James C. Hawley
Vice President, Chief Financial
Officer and Secretary